At present, Neoadjuvant Chemotherapy for the treatment of locally advanced HER2-positive Breast Cancer (BC) includes trastuzumab (Herceptin), a humanized IgG1 monoclonal antibody (mAb) targeting human epidermal growth factor receptor-2 (HER2). Here, ERBB2 is linked to breast carcinoma.